CClinicalTrials.gg
Active, not recruitingNCT07139327ENTERPRISEUpdated Sep 8, 2026

A Pivotal Study to Evaluate the Efficacy and Safety of a Totally Implantable Cochlear Implant (TICI) System in Adults

An interventional study of Cochlear Implant in Hearing Loss, Bilateral Sensorineural, sponsored by Cochlear. Active, not recruiting at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Cochlear · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This clinical study examines the performance of an investigational totally implantable cochlear implant (TICI) system. The system includes an implantable microphone under the skin to detect speech and sound from the environment allowing the option to hear without the need of an external sound processor. This implant will be tested in adults with sensorineural hearing loss, a type of hearing loss caused by damage to the inner ear or auditory nerve (the nerve that carries sound signals from the ear to the brain). The study participants will undergo a series of tests that include testing their implant and their hearing. They will also complete questionnaires to see how they rate their hearing and overall general health.

02

Conditions studied

  • Hearing Loss, Bilateral Sensorineural

Keywords

  • cochlear implant
  • sensorineural hearing loss
03

In context

Hearing Loss

1,093 studies on the registry are indexed under Hearing Loss; 236 are open to participants now.

This study's planned enrollment of 36 is close to the median of 40 across 764 interventional studies indexed under Hearing Loss.

Browse Hearing Loss studies →

Lead sponsor

Cochlear is the lead sponsor of 91 studies on the registry; 11 are open to participants now.

Of its 16 completed or terminated interventional studies of FDA-regulated products, 15 (94%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Individuals aged 18 years and older at time of consent.
  • Clinically established post-linguistic moderately severe to profound sensorineural hearing loss (PTA4 of >55 dB HL), in the ear to be implanted.
  • Meets local candidacy criteria for cochlear implantation.
  • Compromised functional hearing with a hearing aid in the ear to be implanted, as determined by the investigator.
  • Willing to undergo unilateral cochlear implantation.
  • Candidate is a fluent speaker in the language used to assess speech perception performance as determined by the investigator
  • Direct access to a compatible Smart Phone.
  • Willing and able to provide written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Prior cochlear implantation, in either ear, or medical plan for cochlear implantation during the clinical investigation, contralateral to the ear to be implanted.
  • Candidates with single-sided deafness as determined by the investigator.
  • Intra-axial (within-the-brain) lesions or deafness due to lesions of the acoustic nerve affecting the ear to be implanted.
  • Middle ear infection (including acute otitis media, chronic otitis media, suppurative otitis media, or serous drainage) in the ear to be implanted either at the time of surgery or within 3 months prior to enrolment.
  • Presence of a tympanic membrane perforation or a history of otologic surgery within 3 months prior to enrolment, in the ear to be implanted.
  • Previously reported diagnosis of auditory neuropathy, in the ear to be implanted.
  • Cochlear ossification, cochlear malformation or any other cochlear anomaly, such as common cavity, that might prevent complete insertion of the electrode array, in the ear to be implanted.
  • Current cerebrospinal fluid (CSF) shunts or drains, existing perilymph fistula, skull fracture or CSF leaks.
  • Severe, or poorer, bilateral sensorineural hearing loss prior to 5 years of age, as reported by the participant.
  • Severe, or poorer, sensorineural hearing loss for more than 20 years, as reported by the participant, in the ear to be implanted.
  • Medical or psychological conditions that contraindicate general anaesthesia, surgery, or participation in the clinical investigation as determined by the investigator.
  • Preexisting skin condition that could jeopardize wound healing, as determined by the investigator e.g., psoriasis, dermatitis, use of corticosteroids, uncontrolled diabetes.
  • Unrealistic expectations on the part of the participant, regarding the possible benefits, risks, and limitations inherent to the surgical procedure(s) and prosthetic devices, as determined by the Investigator.
  • Additional disabilities that may affect the subject's participation or safety during the clinical investigation.
  • Women who are pregnant.
  • Investigator site personnel directly affiliated with this study and/or their immediate families. Immediate family is defined as spouse, parent, child or sibling.
  • Cochlear employees or employees of Contract Research Organisations or contractors engaged by Cochlear for the purposes of the investigation.
  • Current participation, or participation in another interventional clinical study/trial in the past 30 days, involving an investigational drug or device.
  • Unable or unwilling to comply with the requirements of the clinical investigation as determined by the Investigator (unless Cochlear sponsored and determined by Investigator or Sponsor to not impact this investigation).
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    TICI G2 Clinical Investigation System

    Participants will be implanted with the TICI G2 Implant

    Device: Cochlear Implant

Interventions

  • DeviceCochlear Implant

    TICI G2 Clinical Investigation System

06

What researchers measure

Primary outcomes

  1. Speech recognition performance in quiet

    Percent correct word score from preimplantation to post-activation

    Time frame: Preimplantation to 6 months post-activation

  2. Incidence of adverse events and device deficiencies

    Frequency and severity of device and procedure-related adverse events, including device deficiencies

    Time frame: Implantation to 6 and 12 months post-activation

Secondary outcomes

  1. Speech recognition in quiet and noise

    Percent correct scores for word tests in quiet and speech reception threshold scores for sentence tests in noise

    Time frame: Preimplantation to 12 months post-activation

  2. Speech Spatial Qualities questionnaire (SSQ-12)

    Speech, Spatial, and Qualities of Hearing Scale Global score (SSQ-12). Scores range from 0 to 10, where higher scores indicate greater ability (less hearing disability).

    Time frame: Preimplantation to 12 months post-activation

  3. Cochlear Implant Quality of Life Profile (CIQOL-35)

    Cochlear implant hearing related quality of life score (CIQOL-35). Scored for six health domains (communication, emotional, entertainment, environment, listening effort, and social) each scaled from 0 to 100, where a higher score indicates better health.

    Time frame: Preimplantation to 12-months post-activation

  4. Health Utilities Index (HUI 2/3)

    Health Utilities Index (HUI 2/3) Global score. Scores range from -0.36 to 1.00, where a negative score represents a state "worse than dead" and a top score of 1.00 is "perfect health"

    Time frame: Preimplantation to 12 months post-activation

  5. Living with Cochlear Implants Questionnaire (LivCI)

    Living with Cochlear Implants Questionnaire (LivCI) evaluates the impact of a hearing device on four domains, Participation (range 0 to 12), Psychosocial \& Wellbeing (range 0 to 21), Stigma (range 0 to 15) and Management \& Aesthetics (range 0 to 18), where a higher domain score indicates positive patient report.

    Time frame: Preimplantation to 12 months post-activation

  6. Patient Satisfaction Survey

    Device satisfaction rating score. Scores range from 1 to 5, where a higher score indicates greater patient satisfaction with the TICI system.

    Time frame: 6 to 12 months post-activation

  7. Short Form (SF)-36 Health Survey

    SF-36 is scored for eight health domains, each scaled from 0 to 100, where a higher score indicates better health.

    Time frame: 8 to 10 months post-activation

  8. Time on air

    Hours of TICI System usage

    Time frame: Initial activation to 12 months post-activation

07

Study locations

8 sites
  • Royal Prince Alfred Hospital
    Camperdown, New South Wales 2050, Australia
  • Macquarie University Hospital
    Macquarie, New South Wales 2109, Australia
  • Westmead Private Hospital
    Westmead, New South Wales 2145, Australia
  • Westmead Public Hospital
    Westmead, New South Wales 2145, Australia
  • Royal Victoria Eye and Ear Hospital
    East Melbourne, Victoria 3002, Australia
  • St Vincent's Private Hospital
    East Melbourne, Victoria 3002, Australia
  • Centre Hospitalier Universitaire Grenoble Alpes
    La Tronche, 38700, France
  • Centre Hospitalier Universitaire de Lille
    Lille, 59000, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07139327
Lead sponsor
Cochlear
Responsible party
Sponsor
First posted
Aug 24, 2025
Start date
Dec 1, 2025
Primary completion
Apr 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Sep 8, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion